ROCKVILLE, Md., March 27, 2019 /PRNewswire/ -- RegeneRx
Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on
tissue protection, repair and regeneration, today announced that J.J. Finkelstein, President and Chief Executive Officer,
will present a corporate update at the Spring Investor Summit taking place on April 1-2, 2019 in
New York, NY. Mr. Finkelstein will speak on Tuesday, April 2
at 9:00 a.m. ET. A copy of his presentation will be available on the Company's website
at http://www.regenerx.com/presentations on Tuesday morning.
About RegeneRx Biopharmaceuticals, Inc. (www.regenerx.com)
RegeneRx is focused on the development of novel therapeutic peptides, including Thymosin beta 4 (Tβ4) and its constituent
fragments, for tissue and organ protection, repair and regeneration. RegeneRx currently has three drug candidates in clinical
development for ophthalmic, cardiac and dermal indications, three active strategic licensing agreements in the U.S., China, and Pan Asia (Korea, Japan, and Australia, among others), and has patents and patent applications covering its products in many countries
throughout the world.
RegeneRx, through its U.S joint venture, ReGenTree LLC, sponsored its second Phase 3 clinical trial (ARISE-2) in approximately
600 patients with dry eye syndrome (DES) and reported positive clinical results with no safety issues. ReGenTree recently
initiated ARISE-3, a follow-up Phase 3 trial in 700 patients with DES designed to confirm the positive results from
ARISE-2. ReGenTree is also sponsoring a 46-patient Phase 3 clinical trial in patients with neurotrophic keratopathy
(NK). Additionally, RGN-259 is being developed in patients with dry eye syndrome in Asia
through RegeneRx's two Asian partnerships. RGN-259 has been designated an orphan drug in the U.S. for the treatment of NK.
RGN-352, the Company's Tβ4-based injectable formulation, is a Phase 2-ready drug candidate designed to be administered
systemically to prevent and repair cardiac damage resulting from heart attacks and central nervous system tissue disorders such
as peripheral neuropathy, multiple sclerosis and traumatic brain injuries such as stroke. It may also have applications in
patients with severe septic shock.
RGN-137, also designated an orphan drug in the U.S., is the Company's Tβ4-based dermal gel formulation that is being developed
for epidermolysis bullosa, a rare skin condition. The Company's licensee, GtreeBNT, has initiated a small, open clinical trial in
the U.S. for this indication.
For additional information about RegeneRx please visit www.regenerx.com.
Forward-Looking Statements
Any statements in this press release that are not historical facts are forward-looking statements made under the provisions of
the Private Securities Litigation Reform Act of 1995. Any forward-looking statements involve risks and uncertainties that could
cause actual results to be materially different from historical results or from any future results expressed or implied by such
forward-looking statements. Forward-looking statements used in this press release relate to, among other things, the expected
timing of clinical trials in the United States and the potential patient benefits of its product
candidates. There can be no assurance that any proposed clinical trial will be completed within the estimated timeframe or that
positive results from any clinical trials or research by the Company, its collaborators, or independent parties in the U.S. or
any other country will result in subsequent clinical confirmation or future value. There can also be no assurance that any of the
Company's drug candidates will result in any approved products in the U.S. or any other country. Please view these and other
risks described in the Company's filings with the Securities and Exchange Commission ("SEC"), including those identified in the
"Risk Factors" section of the annual report on Form 10-K for the year ended December 31, 2018, and
subsequent quarterly reports filed on Form 10-Q, as well as other filings it makes with the SEC. Any forward-looking statements
in this press release represent the Company's views only as of the date of this release and should not be relied upon as
representing its views as of any subsequent date. The Company specifically disclaims any obligation to update this information,
as a result of future events or otherwise, except as required by applicable law.
View original content:http://www.prnewswire.com/news-releases/regenerx-to-present-at-2019-spring-investor-summit-300819441.html
SOURCE RegeneRx Biopharmaceuticals, Inc.